The DSO Letter of Intent: What You’re Actually Signing in 2026

He read me the first line over the phone. “This letter is non-binding.”

That was the sentence he had fastened onto, and it was doing an enormous amount of work in his head. Non-binding meant no risk.

No risk meant he could sign it, see what diligence turned up, and walk if he didn’t like where it went.

Then he asked what I thought of the price.

Wrong first question. The price in a letter of intent is the part that is genuinely not binding.

The parts that bind him were on page 4, under a heading he had skimmed past twice.

This is the most expensive misunderstanding in dental transactions, and it is almost universal.

Owners treat the letter as a formality because someone told them it was non-binding. The document they skim is the one that decides their leverage for the next 90 days.

Key takeaways

• An LOI is non-binding on price and binding on leverage. Exclusivity, confidentiality and expense allocation are typically the enforceable provisions. Price, structure and closing date are not.
• Exclusivity is the whole ballgame. Signing it sends every competing bidder home, and you cannot call them back mid-diligence without starting over.
• Anything you leave to “we’ll work it out later” you will probably lose. Rollover, earnout measurement, your hours, non-compete scope and team protections all get harder to move once exclusivity has started.
• Open-ended exclusivity is the clause to fix first. Ask for a defined end date with no automatic extension, and tie any extension to the buyer meeting its own milestones.
• None of this makes buyers the adversary. Exclusivity is standard market practice and entirely reasonable from where they sit. The mistake is signing one before you have used the leverage you had.

What is a DSO letter of intent? A letter of intent is the document that sets out the proposed terms of a sale to a dental support organization before definitive agreements are drafted. Most of it, including price and structure, is non-binding.

Confidentiality, exclusivity and expense allocation usually are binding, and take effect the moment you sign.

One thing before we go further. What follows is general information about how these documents work, not legal advice.

No article can account for your state, your entity structure, or the specific paper in front of you. Have any letter of intent reviewed by an attorney who does dental transactions regularly, before you sign it.

What a letter of intent is, and what it is not

A DSO is a dental support organization — the management company that owns the non-clinical side of a practice and handles everything outside the operatory, while a licensed dentist keeps ownership of the clinical entity.

The letter of intent sits between “we’re interested” and “here are 200 pages of definitive agreements.”

It records what the parties think they have agreed: price, how the price gets paid, what happens to you afterward, and what has to be true for the deal to close.

Mandelbaum Barrett’s walkthrough of the four-phase DSO transaction process describes the letter as setting out the key terms of a proposed transaction while committing the parties to negotiate exclusively for a set period. Both halves of that sentence matter.

Owners hear the first half.

It also arrives later in the sequence than owners expect. A non-disclosure agreement usually comes first, before financials change hands; Mandelbaum Barrett’s seller guide treats the LOI as the step after that, once the buyer has seen enough to put a number on paper.

Here is the honest framing. The LOI is not a contract to sell your practice.

It is a contract about how you will behave while the buyer decides whether to buy it.

That is a real obligation. It just isn’t the one most owners are watching.

Which parts of a DSO letter of intent are binding?

Which provisions of an LOI are legally binding? Typically confidentiality, exclusivity or no-shop, and expense allocation, plus governing law and the letter’s own termination mechanics. Purchase price, deal structure, rollover percentage, earnout targets and closing date are usually expressed as non-binding.

Break fees appear occasionally and are binding when they do.

The asymmetry is the point, and once you see it you cannot unsee it.

Provision	Typically binding?	What it actually does
Purchase price	No	Sets an expectation the buyer can revisit if diligence changes the picture
Asset vs equity structure	No	Signals intent; the tax consequences get papered later
Rollover equity percentage	No	Often stated as a range, and ranges move
Earnout targets	No	Frequently left vague at this stage, which is the problem
Closing date	No	A target, not a commitment
Your post-sale role and hours	No	Almost always deferred to the employment agreement
Confidentiality	Yes	Binds you not to disclose the discussions, and often binds both sides
Exclusivity / no-shop	Yes	Bars you from talking to any other buyer for the stated period
Expense allocation	Yes	Each side normally bears its own costs, win or lose
Non-solicitation during the period	Sometimes	Can restrict hiring across both parties while talks run
Break fee	Occasionally	A payment if you walk; read this one twice if it appears
Governing law and dispute resolution	Yes	Determines where any fight over the binding parts happens

Read the column again. Every provision that constrains you is binding.

Every provision that protects you is not.

That is not a trick anyone is playing. It is the natural shape of a document drafted by the party about to spend money on diligence.

It matches the general M&A pattern transaction counsel describe: the reliably binding elements are exclusivity, confidentiality and expense terms.

A buyer about to pay accountants and lawyers wants certainty that you are not shopping their number. Fair.

But you should sign it knowing which way the ratchet turns.

What exclusivity actually costs

Exclusivity, sometimes called a no-shop, is your agreement not to solicit, entertain or negotiate with any other buyer for a defined stretch of time.

The cost of it is not theoretical. It is the disappearance of every alternative you had.

Picture the week before you sign. Three organizations have shown interest.

Two have asked for financials. One keeps calling.

You have options, and options are what make a buyer careful about their number.

Now picture the week after. There is one buyer.

There is no second conversation to fall back on.

Ahead of you sit 60 to 90 days of diligence in which the buyer learns everything about your practice and you learn nothing new about your alternatives.

If the number moves down during that window, you meet it with nothing. That is the re-trade, and I walked through its mechanics in our piece on how long it takes to sell a dental practice.

Not because the buyer behaved badly. Because you signed away the only thing that made them stretch.

Competitive tension has to be created before the LOI. After it, there is nothing left to create it with.

I want to be careful here, because sellers sometimes get told a story that isn’t true.

Exclusivity is not sharp practice. Nearly every serious buyer asks for it, for sound commercial reasons, and one who did not ask would be unusual.

The problem has never been that buyers request exclusivity. It is that owners hand it over before using the leverage they had.

How long should exclusivity run?

How long should a DSO exclusivity period last? Anchor it to the diligence the buyer actually needs, commonly 60 to 90 days for a single-location dental practice, with a hard end date and no automatic rollover. Multi-site groups and deals requiring state regulatory notice justify longer.

Any extension should require the buyer to have met defined milestones.

Exclusivity periods have been stretching across M&A generally.

Goodwin’s review of private equity deal terms found that in 2021 only 6% of transactions carried exclusivity of 61 days or more. By 2022 nearly 40% did, most running at least 76 days.

So a 90-day request is not outrageous on its face. An open-ended one is a different animal.

Watch for three specific things in the clause.

Automatic extension. Some drafts extend exclusivity by another 30 days unless someone affirmatively terminates. That converts a 60-day commitment into an indefinite one through inertia.

Extension tied to nothing. If the buyer can extend simply by asking, the deadline is decorative. Tie any extension to the buyer having delivered its diligence list, funded its costs, and confirmed the price in writing.

A period with no exit. You want a right to terminate if the buyer materially changes the economic terms. Without it, a re-trade in week 7 leaves you locked in for the remaining weeks with a number you never agreed to.

There is a real reason some deals need longer, and it is worth naming. State oversight of these structures has expanded fast.

In California, private equity groups, hedge funds and management services organizations became noticing entities as of January 1, 2026. Goodwin’s tracker of state healthcare transaction notification laws puts the requirement at 90 days’ notice before closing, with reviews that can run 90 to 180 days.

Those rules carry revenue and value thresholds. A single-location practice generally sits well outside them; a larger multi-site group may not.

Nixon Peabody counted a flurry of comparable state activity on private equity in healthcare in the opening weeks of 2026. Hinshaw’s read on the compliance standards that followed the California Aspen Dental settlement shows where the structuring bar now sits.

Underneath all of it is the corporate practice of dentistry: the state laws restricting who can own or control a dental practice, catalogued in the House Oversight Committee’s 50-state survey.

Those laws are why the structure exists. An MSO is the management services organization a DSO uses to own the non-clinical side, because most states bar non-dentists from owning the clinical practice.

If you are selling a group of any size, ask early whether a filing applies. It belongs in the exclusivity math, not as a surprise in month 3.

What should be settled in the LOI rather than left for later

This is the section I would tape to the wall.

Owners routinely sign an LOI that nails the price and defers everything else to “the definitive documents.”

Then they discover those documents are drafted by the buyer’s counsel and negotiated under exclusivity, so every open item resolves toward the party with alternatives. Which is not them.

A useful test for any term: would I still be able to walk away over this? If the answer is no once exclusivity starts, put it in the letter.

Settle it in the LOI	Reasonably deferred to definitive documents
Price and how it is calculated (the EBITDA definition itself)	Working capital true-up mechanics
Cash at closing versus deferred consideration	Form of the holdback release schedule
Rollover percentage and which entity the equity sits in	Minority-holder governance boilerplate
Earnout targets and exactly how they are measured	Reporting format and timing
Your post-sale clinical role, hours and compensation method	Benefits administration detail
Non-compete geography and duration	Standard confidentiality and IP language
Team retention commitments and any pay protections	Payroll transition logistics
Practice name and brand retention	Signage vendor and timeline
Purchase price allocation approach for tax	Schedule mechanics on the tax forms

A few of these deserve their own paragraph, because they are where I see the most value quietly leak.

Rollover equity, and the entity it lives in. Rollover equity means keeping a slice of ownership in the buyer’s company instead of taking all cash at close. Mandelbaum Barrett puts the cash portion of a dental deal at roughly 60% to 80% of the price, with the balance in equity that is frequently illiquid and governed by restrictive agreements.

The question almost nobody asks is which entity issues that equity.

Nixon Peabody’s analysis of the second exit explains why it matters: rollover typically sits in the common equity position, behind debt, behind sponsor preferred returns, and behind transaction fees.

So the headline price when the platform sells is not the number that determines your payout. The waterfall is.

Earnout measurement, not just the target. An earnout is part of the price paid later, only if the practice hits agreed targets after closing. Getting the target into the LOI is the easy half.

The hard half is defining who calculates it, from which financial statements, and which of the buyer’s costs land on your location.

Nixon Peabody’s list of issues to address before signing puts purchase price mechanics, working capital adjustments, holdbacks and the EBITDA calculation itself at the centre of where disputes start.

A target measured on numbers the other side controls is not really a target.

Your role and your hours. Cranfill Sumner notes that the selling doctor is typically required to work for the buyer for a minimum defined period after closing, commonly 3 to 5 years. That is a long commitment to leave to a document you have not seen.

Hours, production expectations, compensation method, and what happens if the model changes all belong in the letter, at least in outline.

Non-compete scope. This one has moved recently. The FTC’s federal non-compete rule was enjoined in court and never took effect, as Hinshaw tracked at the time.

State law went the other way. Washington enacted a sweeping ban in 2026, Virginia widened its restrictions effective July 1, 2026, and Benesch’s 2025 restrictive-covenant review counted 4 states banning non-competes outright with more than 30 restricting them.

Sale-of-practice covenants are treated differently from ordinary employment covenants in many states. That is precisely why geography and duration should be specific in the LOI rather than assumed.

Purchase price allocation. How the price is split across asset classes changes what you keep after tax, and both sides must report the allocation consistently on IRS Form 8594. Agreeing the approach in the LOI costs nothing.

Discovering the buyer’s preferred allocation in the final week costs real money.

Team and brand. These are not sentimental items. If keeping your practice name or protecting your hygiene team’s pay structure matters to you, it is a term.

Terms go in writing early or they evaporate.

What to do before you sign

Two things, in order.

First, know your real number. Dental owners think in collections and overhead percentage. Buyers think in adjusted EBITDA, which is what the practice earns in pure operating profit after paying a market-rate dentist to do the work you currently do yourself.

The bridge runs: collections, minus true operating overhead, minus a market-rate associate’s compensation for your own production, equals adjusted EBITDA. Multiply that by the multiple and you have enterprise value.

That is the adjusted EBITDA figure a buyer prices off.

That last subtraction is the one owners miss, and it is usually the largest.

A “percentage of collections” figure and an EBITDA multiple are not comparable numbers. An offer quoted one way cannot be judged against a market quoted the other.

If you have not done that arithmetic, you cannot evaluate the price in the letter. Our guide to what your dental practice is worth walks through it.

Second, get the financials reviewed before the buyer’s accountants get to them. When we prepare a practice for sale, part of the work is a thorough pre-sale financial review on our side of the table, built around the same scrutiny the buyers’ accountants will apply, but months before any buyer sees a number.

Every add-back gets evidenced. Every lease term, employment agreement and corporate record gets checked.

Anything that would not survive a deep look gets found and fixed while you still hold every option.

The point is narrow and specific: an owner who has already been through that review meets diligence with nothing left to discover. No new information means no reason to revisit the price. The number in the letter becomes the number at closing.

That is the whole defence against a re-trade, and it has to happen before the letter is signed, not after.

Where the leverage actually comes from

Here is the part that reframes everything above.

Every problem in this article — exclusivity you cannot escape, terms you cannot move, a price you cannot defend — is a symptom of one condition. You are talking to one buyer.

The buyer pool is not thin. The Association of Dental Support Organizations counts 80-plus DSO member companies supporting thousands of practices, and Becker’s reported that 69% of DSOs said their sponsors expected a moderate or high increase in acquisition activity in 2026.

Meanwhile the supply of independent owners keeps shrinking. ADA Health Policy Institute data puts private practice ownership at 72.5% of US dentists in 2023, down from 84.7% in 2005.

DSO affiliation reached 16.1% in 2024, and 27% among dentists less than 10 years out of school.

Well-funded buyers competing for a shrinking pool of practices. Scarcity is on your side of the table, and a single-bidder letter of intent hands it straight back.

This is the logic behind the Elite Selling System.

We hand-select and vet every buyer who gets to bid on your practice, the way a doorman with a velvet rope lets in only the right people, then run a private competitive window inside that vetted group.

A letter that arrives at the end of that process reads differently from one that arrives unsolicited. The buyer knows what they had to beat.

The terms are better for the same reason the price is better. A buyer who competed for your practice is far less inclined to test whether the number can move in week 7.

If you want to see who those buyers actually are, we keep a current view of who is buying dental practices and what each type of acquirer is looking for.

What to do next

If a letter of intent is in front of you right now, the sequence is simple.

Do not sign it this week. Get your adjusted EBITDA documented and independently reviewed.

Have an attorney experienced in dental transactions read the binding provisions.

Then find out what the practice would draw from more than one qualified buyer, before you agree to speak to only one.

If a letter is coming but has not arrived, you are in the strongest position you will ever be in, and most owners spend it waiting.

We will tell you where you stand, free and in confidence, including the answer that the offer in your hand is already a good one and you should take it, when that is the honest answer.

It starts with a free, confidential practice value estimate.

Our fee varies depending on the value of the practice and is entirely success-based. If we do not get you a result, we do not get paid.

---

Frequently asked questions

Is a DSO letter of intent legally binding?

Mostly not, but partly yes. Price, structure, rollover percentage, earnout targets and the closing date are typically expressed as non-binding.

Confidentiality, exclusivity or no-shop, expense allocation and governing law are usually binding and take effect on signature.

What does exclusivity in an LOI actually mean?

You agree not to solicit, entertain or negotiate with any other buyer for a defined period. Competing bidders go away, and if the price is revisited during diligence you have no alternative.

Competitive tension has to be created before you sign.

How long should a DSO exclusivity period last?

Match it to the diligence genuinely required, commonly 60 to 90 days for a single-location practice, with a hard end date. Avoid automatic extensions, tie any extension to the buyer meeting defined milestones, and keep a right to terminate if the economic terms change.

Can I negotiate a letter of intent, or is it take it or leave it?

You can negotiate it, and the LOI stage is when you have the most leverage you will ever have. Once exclusivity begins, every open item gets resolved in favour of the party with alternatives, which is no longer you.

What terms should be settled in the LOI rather than the definitive agreements?

Price and the EBITDA definition behind it, cash at closing versus deferred consideration, rollover percentage and which entity issues the equity, earnout targets and how they are measured, your post-sale role and hours, non-compete scope, team protections, brand retention, and the tax allocation approach.

Do I need a lawyer to review a letter of intent?

Yes. This article is general information, not legal advice.

The binding provisions are enforceable the moment you sign, and state rules on restrictive covenants and the corporate practice of dentistry vary enough that a dental transactions attorney is the right reader.

What is rollover equity and why does the entity matter?

Rollover equity means keeping a slice of ownership in the buyer’s company instead of taking all cash at close. It usually ranks behind debt, sponsor preferred returns and transaction fees, so the issuing entity decides what you actually receive at the next exit.

Are DSOs being unreasonable by asking for exclusivity?

No. Exclusivity is standard market practice and commercially sensible for a buyer about to spend real money on diligence.

Nearly every serious acquirer asks for it. The risk is that owners grant it before establishing what competing buyers would pay.

---

Sources

Transaction documents and the DSO deal process

1. Mandelbaum Barrett PC. “The Four-Phase DSO Transaction Process: What to Expect When Selling a Dental Practice.” mblawfirm.com
2. Mandelbaum Barrett PC. “A Guide to Selling Your Dental Practice to a Dental Service Organization.” mblawfirm.com
3. Mandelbaum Barrett PC. “Navigating Types of Dental Transactions and the Financial Terms to Know.” mblawfirm.com
4. Cranfill Sumner LLP. “Selling Your Dental Practice to a DSO: What to Expect Before, During, and After the Deal.” cshlaw.com
5. Nixon Peabody LLP. “Five Issues Dentists and DSOs Should Address Before Signing a Transaction.” July 2026. nixonpeabody.com

Exclusivity, rollover equity and restrictive covenants

6. Goodwin. “Durations in M&A Exclusivity Periods Increased Significantly Since 2021.” goodwinlaw.com
7. Nixon Peabody LLP. “The Second Exit: What Happens to Physician Rollover Equity When the Platform Sells.” March 2026. nixonpeabody.com
8. Hinshaw & Culbertson LLP. “FTC Faces Setback in U.S. District Court Over Noncompete Rule.” hinshawlaw.com
9. Holland & Knight. “Washington State Bans Non-Compete Agreements.” March 2026. hklaw.com
10. Holland & Knight. “Virginia Expands Restrictions Against Employee Non-Competes.” April 2026. hklaw.com
11. Benesch. “2025 Trade Secret and Restrictive Covenant Year in Review.” beneschlaw.com

Regulation of DSO and MSO transactions

12. Goodwin. “State Healthcare Transaction Notification Laws — California.” goodwinlaw.com
13. Nixon Peabody LLP. “2026 Starts With a Flurry of State Activity on Private Equity and Healthcare.” January 2026. nixonpeabody.com
14. Hinshaw & Culbertson LLP. “A New Era of Compliance Standards for California DSOs and MSOs After the Aspen Dental Settlement.” hinshawlaw.com
15. US House Committee on Oversight. “Survey of State Laws Governing the Corporate Practice of Dentistry.” oversight.house.gov

Tax

16. Internal Revenue Service. “Instructions for Form 8594, Asset Acquisition Statement.” irs.gov

Buyer market and dental practice economics

17. Association of Dental Support Organizations. “About ADSO.” theadso.org
18. Becker’s Dental Review. “69% of DSOs Plan to Boost Acquisitions in 2026: Report.” beckersdental.com
19. ADA Health Policy Institute. “Practice Ownership Trends in Dentistry: A New Look at Old Data.” ada.org
20. ADA Health Policy Institute. “Dental Practice Research — DSO Affiliation.” ada.org